119 related articles for article (PubMed ID: 7511719)
1. Cytokines in acute myocardial infarction: selective increase in circulating tumor necrosis factor, its soluble receptor, and interleukin-1 receptor antagonist.
Latini R; Bianchi M; Correale E; Dinarello CA; Fantuzzi G; Fresco C; Maggioni AP; Mengozzi M; Romano S; Shapiro L
J Cardiovasc Pharmacol; 1994 Jan; 23(1):1-6. PubMed ID: 7511719
[TBL] [Abstract][Full Text] [Related]
2. [The protective effect of interleukin-1 receptor antagonist on postischemic reperfused myocardium and its possible mechanism].
Li YJ; Ding WH; Gao W; Huo Y; Hong T; Zhu RY; Ma DL
Zhonghua Yi Xue Za Zhi; 2004 Apr; 84(7):548-53. PubMed ID: 15144587
[TBL] [Abstract][Full Text] [Related]
3. Interleukin-1 beta induces interleukin-1 receptor antagonist and tumor necrosis factor binding protein in humans.
Bargetzi MJ; Lantz M; Smith CG; Torti FM; Olsson I; Eisenberg SP; Starnes HF
Cancer Res; 1993 Sep; 53(17):4010-3. PubMed ID: 8395334
[TBL] [Abstract][Full Text] [Related]
4. Persistently elevated soluble tumor necrosis factor receptor and interleukin-1 receptor antagonist levels in critically ill patients.
Rogy MA; Coyle SM; Oldenburg HS; Rock CS; Barie PS; Van Zee KJ; Smith CG; Moldawer LL; Lowry SF
J Am Coll Surg; 1994 Feb; 178(2):132-8. PubMed ID: 8173722
[TBL] [Abstract][Full Text] [Related]
5. Plasma and urinary cytokine homeostasis and renal function during cardiac surgery without cardiopulmonary bypass.
Gormley SM; McBride WT; Armstrong MA; McClean E; MacGowan SW; Campalani G; McMurray TJ
Cytokine; 2002 Jan; 17(2):61-5. PubMed ID: 11886172
[TBL] [Abstract][Full Text] [Related]
6. Balance between IL-1 beta, TNF-alpha, and their specific inhibitors in chronic renal failure and maintenance dialysis. Relationships with activation markers of T cells, B cells, and monocytes.
Descamps-Latscha B; Herbelin A; Nguyen AT; Roux-Lombard P; Zingraff J; Moynot A; Verger C; Dahmane D; de Groote D; Jungers P
J Immunol; 1995 Jan; 154(2):882-92. PubMed ID: 7814891
[TBL] [Abstract][Full Text] [Related]
7. Interleukin-1 and tumor necrosis factor-alpha in plasma of patients with acute ischemic heart disease who undergo thrombolytic therapy: a randomized, placebo-controlled study.
Munkvad S; Gram J; Jespersen J
Lymphokine Cytokine Res; 1991 Aug; 10(4):325-7. PubMed ID: 1932377
[TBL] [Abstract][Full Text] [Related]
8. Proinflammatory cytokines and myocardial viability in patients after acute myocardial infarction.
Kosmala W; Przewlocka-Kosmala M; Mazurek W
Int J Cardiol; 2005 Jun; 101(3):449-56. PubMed ID: 15907414
[TBL] [Abstract][Full Text] [Related]
9. Hydroxyl radical generation, levels of tumor necrosis factor-alpha, and progression to heart failure after acute myocardial infarction.
Valgimigli M; Merli E; Malagutti P; Soukhomovskaia O; Cicchitelli G; Antelli A; Canistro D; Francolini G; Macrì G; Mastrorilli F; Paolini M; Ferrari R
J Am Coll Cardiol; 2004 Jun; 43(11):2000-8. PubMed ID: 15172404
[TBL] [Abstract][Full Text] [Related]
10. Tumor necrosis factor-alpha receptor 1 is a major predictor of mortality and new-onset heart failure in patients with acute myocardial infarction: the Cytokine-Activation and Long-Term Prognosis in Myocardial Infarction (C-ALPHA) study.
Valgimigli M; Ceconi C; Malagutti P; Merli E; Soukhomovskaia O; Francolini G; Cicchitelli G; Olivares A; Parrinello G; Percoco G; Guardigli G; Mele D; Pirani R; Ferrari R
Circulation; 2005 Feb; 111(7):863-70. PubMed ID: 15699251
[TBL] [Abstract][Full Text] [Related]
11. Circulating tumor necrosis factor-alpha levels in chronic heart failure: relation to its soluble receptor II, interleukin-6, and neurohumoral variables.
Koller-Strametz J; Pacher R; Frey B; Kos T; Woloszczuk W; Stanek B
J Heart Lung Transplant; 1998 Apr; 17(4):356-62. PubMed ID: 9588580
[TBL] [Abstract][Full Text] [Related]
12. Circulating interleukin-1 and tumor necrosis factor antagonists in liver disease.
Tilg H; Vogel W; Wiedermann CJ; Shapiro L; Herold M; Judmaier G; Dinarello CA
Hepatology; 1993 Nov; 18(5):1132-8. PubMed ID: 8225219
[TBL] [Abstract][Full Text] [Related]
13. Evidence against a role for polymorphisms at tumor necrosis factor, interleukin-1 and interleukin-1 receptor antagonist gene loci in the regulation of disease severity in acute pancreatitis.
Powell JJ; Fearon KC; Siriwardena AK; Ross JA
Surgery; 2001 May; 129(5):633-40. PubMed ID: 11331456
[TBL] [Abstract][Full Text] [Related]
14. Interleukin-1 receptor antagonist, soluble tumor necrosis factor-alpha receptor type I and II, and soluble E-selectin serum levels in multiple sclerosis patients receiving weekly intramuscular injections of interferon-beta1a.
Perini P; Tiberio M; Sivieri S; Facchinetti A; Biasi G; Gallo P
Eur Cytokine Netw; 2000 Mar; 11(1):81-6. PubMed ID: 10705303
[TBL] [Abstract][Full Text] [Related]
15. Circulating levels of tumor necrosis factor soluble receptors in systemic lupus erythematosus are significantly higher than in other rheumatic diseases and correlate with disease activity.
Gabay C; Cakir N; Moral F; Roux-Lombard P; Meyer O; Dayer JM; Vischer T; Yazici H; Guerne PA
J Rheumatol; 1997 Feb; 24(2):303-8. PubMed ID: 9034987
[TBL] [Abstract][Full Text] [Related]
16. Pretreatment cytokine profiles of peripheral blood mononuclear cells and serum from patients with rheumatoid arthritis in different american college of rheumatology response groups to methotrexate.
Seitz M; Zwicker M; Villiger PM
J Rheumatol; 2003 Jan; 30(1):28-35. PubMed ID: 12508386
[TBL] [Abstract][Full Text] [Related]
17. Interleukin 1 (IL-1) receptor antagonist, soluble tumor necrosis factor receptors, IL-1 beta, and IL-8--markers of remission in rheumatoid arthritis during treatment with methotrexate.
Seitz M; Loetscher P; Dewald B; Towbin H; Rordorf C; Gallati H; Gerber NJ
J Rheumatol; 1996 Sep; 23(9):1512-6. PubMed ID: 8877917
[TBL] [Abstract][Full Text] [Related]
18. Interleukin 1 beta, tumour necrosis factor-alpha and interleukin 1 receptor antagonist in newly diagnosed insulin-dependent diabetes mellitus: comparison to long-standing diabetes and healthy individuals.
Netea MG; Hancu N; Blok WL; Grigorescu-Sido P; Popa L; Popa V; van der Meer JW
Cytokine; 1997 Apr; 9(4):284-7. PubMed ID: 9112337
[TBL] [Abstract][Full Text] [Related]
19. Plasma levels of interleukin-1 receptor antagonist (IL-1ra) and severity of illness in patients with burns.
Endo S; Inada K; Yamada Y; Kasai T; Takakuwa T; Nakae H; Kamei Y; Shimamura T; Suzuki T; Taniguchi S; Yoshida M
J Med; 1996; 27(1-2):57-71. PubMed ID: 8863178
[TBL] [Abstract][Full Text] [Related]
20. Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction.
Zwerina J; Hayer S; Tohidast-Akrad M; Bergmeister H; Redlich K; Feige U; Dunstan C; Kollias G; Steiner G; Smolen J; Schett G
Arthritis Rheum; 2004 Jan; 50(1):277-90. PubMed ID: 14730626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
